Category: Biotechnology
![TODAY: Gb Sciences Describes Drug Development Progress in Pharma's Almanac Journal Article](https://cdn.nwe.io/files/x/6f/35/67f3714f135f0cb925f77936e91e.jpg)
Gb Sciences is focusing considerable resources on bringing its lead Parkinson's disease formulations to the clinic with promising results; plus, new data validating the efficacy of their novel anxiety formulations and demonstrating the improved stability of their oral nanoparticle-encapsulated chronic pain formulations add value to their drug development pipeline.
![TODAY: Gb Sciences Showcases Its PhAROS™ Drug Discovery Platform at the 2nd ALCOR Drug Discovery Platform Summit](https://cdn.nwe.io/files/x/85/02/e7e926405af6266be3515bcaa73e.jpg)
President and Chief Science Officer Dr. Andrea Small-Howard demonstrates the platform's utility for predicting novel plant-inspired drug candidates and describes its role in Gb Sciences' future successes
![TODAY: Gb Sciences' Novel Plant-Inspired Pain Medications Featured at SMi's 22nd Annual Pain Therapeutics Conference](https://cdn.nwe.io/files/x/6c/67/9bbf2466e1e391622e9d2032a80e.jpg)
President and Chief Science Officer Dr. Andrea Small-Howard stressed the importance of developing their innovative, plant-inspired formulations as a potentially safer alternative to existing opioid-based pain medications.
![UPDATE: Gb Sciences Issues Shareholder Letter](https://cdn.nwe.io/files/x/16/cb/9bcad2a1b58369c15c44f0f95743.jpg)
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021
![Gb Sciences Issues Shareholder Letter](https://cdn.nwe.io/files/x/16/cb/9bcad2a1b58369c15c44f0f95743.jpg)
Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2022 and key developments from 2021
![Gb Sciences Granted U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary Cystitis](https://cdn.nwe.io/files/x/fa/cf/47921f3fbb05d727375811ddcc47.jpg)
This new patent covers receptor-targeted formulations for the treatment of cardiac hypertrophy, TRPV1-receptor-associated hearing loss and urinary cystitis.
![Gb Sciences and Michigan State University Researchers Have Identified the Complicated Truth Behind the Opportunity for an Effective Cannabinoid-Based Coronavirus Treatment](https://cdn.nwe.io/files/x/31/ea/b3bbd744a893c346807df027298a.jpg)
Gb Sciences' collaboration with MSU has received media coverage across the country, starting with an interview from WLNS-TV in Lansing, Michigan, and interviews with Gb Sciences in the magazines 'Cannabis Business Times' and 'Hemp Grower'
![Gb Sciences Targets COVID-19 Treatment as Omicron Variant Arrives](https://cdn.nwe.io/files/x/fb/e1/63ec6e82b7b6993a3737cb559e34.jpg)
Biopharmaceutical research company leverages positive data on its cannabinoid-containing mixtures to develop new cytokine release syndrome therapies
![Gb Sciences Accelerates Drug Development via Innovative Biopharma Technology and Strategic Partnerships](https://cdn.nwe.io/files/x/f0/ba/60bc037b2a401866c0646831f64d.jpg)
Biopharmaceutical research company pursues faster route for drug discovery using PhAROS™, Gb Sciences' AI-enabled drug discovery platform, and through efficiency in their drug development pipeline leveraging strong relationships
![Gb Sciences Starts Preclinical Study for Plant-Based Formulas to Treat Depression and Anxiety](https://cdn.nwe.io/files/x/4b/41/9d8982cd31a7cf52bcf442a16dea.jpg)
The biopharma technology company's AI-driven PhAROS™ platform has identified novel, plant-inspired formulations that will be tested using preclinical Zebrafish models at the National Research Council of Canada.
![Gb Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related Hyperinflammation](https://cdn.nwe.io/files/x/d1/a0/e649f9b0be535f9163fc15e32459.jpg)
Based on a recently completed preclinical study performed at Michigan State University, Gb Sciences' preclinical data supports further development of their novel cannabinoid-containing complex mixtures as anti-inflammatory therapies for hyperinflammatory conditions associated with COVID-19 and other life-threatening inflammatory conditions.
![Gb Sciences Presenting COVID-Related Cytokine Release Syndrome Results at H.C. Wainwright's 23rd Annual Global Investment Conference](https://cdn.nwe.io/files/x/01/32/981dd6bd19c0cd1d0aeb7828b1f9.jpg)
Highlighting Gb Sciences' Development of Plant-Inspired Therapies for COVID-related Cytokine Release Syndrome, Chronic Pain, and Parkinson's Disease during the Healthcare & Biotech Track starting Monday, September 13.